歌禮製藥-B(01672.HK)初段曾彈近21% 新冠及猴痘病毒抑制劑獲美國專利授權
歌禮製藥-B(01672.HK)扭上日跌勢,今日(20日)高開14.45%,報3.96元後,初段最高曾見4.18元,升20.8%。屆今早9時55分,現報3.88元,升12.14%,成交905.1萬股,涉資3,662.39萬元。
公司公布,口服病毒聚合(酉每)抑制劑ASC10和衍生物用於治療新冠病毒、猴痘病毒及人呼吸道合胞病毒(RSV)等多種病毒感染的化合物專利及其用途專利申請收到美國專利與商標局(USPTO)的授權公告通知書。ASC10由公司完全自主研發,是一款口服雙前藥,口服給藥後,ASC10和莫諾拉韋均可在體內快速、完全轉換為相同的活性藥物ASC10-A。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.